ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
26 août 2024 05h00 HE
|
ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Achieves Debt-Free Status, Boosts Financial Flexibility
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
12 août 2024 11h00 HE
|
Zealand Pharma
Press Release – No. 8 / 2024 Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results Copenhagen, Denmark, August 12,...
ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides
09 août 2024 05h00 HE
|
ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Pursues Neurological Approach to Treating Weight Loss and Eating Disorders through Melanocortin Receptor Binding Peptides
ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS
08 août 2024 05h00 HE
|
ANEW MEDICAL, INC.
ANEW MEDICAL, INC. Announces Patents Issued in Major Asian Markets for use of Genetic Therapy in the Treatment of Alzheimer’s Disease and ALS
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
07 août 2024 16h11 HE
|
Catalyst Pharmaceuticals, Inc.
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million,...
Inozyme Pharma Reports Second Quarter 2024 Financial Results and Provides Business Highlights
06 août 2024 08h30 HE
|
Inozyme Pharma Inc.
Inozyme reported financial results for the second quarter ended June 30, 2024, and provided business highlights.
Quoin Pharmaceuticals to Initiate Clinical Study for Peeling Skin Syndrome
06 août 2024 05h00 HE
|
Quoin Pharmaceuticals, Inc.
Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening...
Baylor Genetics and Baylor College of Medicine Announce New Lab Agreement with Shared Commitment to Innovation and Rapid Implementation to get Critical Testing to Patients
05 août 2024 10h00 HE
|
Baylor Genetics
Baylor Genetics and the Department of Molecular and Human Genetics at Baylor College of Medicine have entered a new lab agreement.
Travere Therapeutics Reports Second Quarter 2024 Financial Results
01 août 2024 16h01 HE
|
Travere Therapeutics, Inc.
Received 521 new patient start forms (PSFs) for FILSPARI® (sparsentan) in the quarter representing the sixth consecutive quarter of PSF growth; Total of 2,484 PSFs received since launch Net product...
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
30 juil. 2024 08h38 HE
|
Zevra Therapeutics
CELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company) a rare disease therapeutics company, today announced that it will host a...